Testosterone: ultra-long ester
Testosterone Undecanoate (Injectable)
Testosterone Undecanoate (Injectable) after one dose: 50% at ~53 days, 25% at 106 days, 12.5% at 159 days.
Drawn from the half-life in the app's model, ~53 days. The model's figures
- Compound
- Testosterone Undecanoate (Injectable)
- Symbol
- TU
- Family
- Testosterone esters
- Parts
- 15
- References
- 22
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Testosterone undecanoate injection is an oily solution of testosterone undecanoate, an ester of testosterone, given into a muscle.1 In the US it is sold as Aveed (Endo), 750 mg in 3 mL, and the UK label for Nebido (Grunenthal) lists 1000 mg in 4 mL, both at 250 mg per mL.1,2
The Aveed label states that it is indicated for testosterone replacement therapy in adult males with primary or hypogonadotropic hypogonadism, and that safety and efficacy in men with “age-related hypogonadism” have not been established.1 The label carries a boxed warning for serious pulmonary oil microembolism (POME) reactions and anaphylaxis, and states that Aveed is available only through a restricted program, the Aveed REMS Program.1
The half-life of 53 days (1272 hours) and time to peak of 14 days (336 hours) above are the app's; the FDA review of Aveed reports a mean half-life of 53.46 days and a median time to peak of 14 days in a single-dose study of 14 men.3 The 95% bioavailability is the app's figure, and none of the cited sources gives a bioavailability percentage for the injection. The “Strong evidence” tag is the app's own grade, and none of the cited sources grades evidence.
How it works
Sources in this part
The Aveed label states that testosterone is formed by cleavage of the ester side chain of testosterone undecanoate, and that tissue esterases release testosterone.1 The Nebido label describes a depot from which the compound is “gradually released” and “almost completely cleaved by serum esterases into testosterone and undecanoic acid”.2
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~53 days
- Bioavailability
- 95%
- Typical dose
- 750–1000 mg
- Route
- IM
- Time to peak
- ~14 days
The Aveed label states no half-life for testosterone undecanoate; it states that the half-life of testosterone itself, as reported in the literature, ranges from 10 to 100 minutes.1 The half-lives that sources do report for the injection range from 18.3 days to 90 days and are not all the same kind of measurement: Zhang and colleagues give a terminal elimination half-life after one injection, and the Nebido label gives a half-life of the release rate from the depot.4,2
| Measure | Figure | Source and note |
|---|---|---|
| Half-life, FDA review, study JPH01495 | Mean 53.46 days | One 1000 mg injection in 14 hypogonadal men in Europe, serum testosterone measured up to 8 weeks after the dose; mean Cmax about 700 ng/dL (one man 1177 ng/dL on day 3) and median (range) time to peak 14 (3 to 21) days.3 |
| Half-life, Behre and colleagues, 1999 | 33.9 ± 4.9 days (castor oil); 20.9 ± 6.0 days (tea seed oil) | Mean ± SEM; one 1000 mg injection in 14 and in 7 hypogonadal men.5 |
| Terminal elimination half-life, Zhang and colleagues, 1998 | 18.3 ± 2.3 days (500 mg); 23.7 ± 2.7 days (1000 mg) | Eight men with Klinefelter's syndrome given one dose and, three months later, the other, except one man who did not receive the 1000 mg dose; the ± values are as printed and the record does not say SD or SEM.4 |
| Release half-life, Nebido label (UK) | 90 ± 40 days | Stated for the release rate after intramuscular injection of the depot.2 |
| Time to peak, Aveed label | Median 7 days (range 4 to 42 days) | Serum testosterone after 750 mg; the FDA review gives a median of 7 days and a Cmax of 611 (224) ng/dL after a first 750 mg injection in 19 men.1,3 |
| Time to peak, Nebido label (UK) | Mean Cmax after 7 days | Mean Cmax of 38 nmol/L (11 ng/mL) after a first 1000 mg injection in hypogonadal men; Zhang and colleagues report raised mean serum testosterone by the end of the first week.2,4 |
| Steady state after 750 mg, Aveed label | Cavg 495 (142), Cmax 891 (345), Cmin 324 (99) ng/dL | Mean (SD) testosterone in 117 men over the interval after the third injection; steady state came with the third injection at 14 weeks. Levels were inversely correlated with body weight: average 426 ± 104 ng/dL in 60 men at 100 kg or more and 568 ± 139 in 57 men at 65 to 100 kg. The FDA review describes a post hoc exploratory analysis by BMI with the same direction: mean Cave 578, 567 and 445 ng/dL for BMI under 26, 26 to 30 and over 30 kg/m2.1,3 |
| Bioavailability | 95% | The app's figure; none of the cited sources gives a bioavailability percentage for the injection. |
Level curve between doses
The chart below draws a one-compartment model with the app's half-life of 1272 hours and time to peak of 336 hours; it is an illustration and not a measured or predicted level for any person. The intervals follow the sources: every 6 weeks in Nieschlag and colleagues, every 10 weeks on the Aveed label, every 12 weeks as the median individually titrated interval in Shankara Narayana and colleagues' hypogonadal and transgender men, and every 14 weeks as the upper end of the Nebido label range.6,1,7,2
What testosterone undecanoate injection products contain per mL
Both labels give the strength as testosterone undecanoate, and the Nebido label states that 250 mg per mL corresponds to 157.9 mg testosterone per mL.1,2
| Product | Maker | Strength | Container | Other contents |
|---|---|---|---|---|
| Aveed (US)1 | Endo USA, Inc. | 250 mg per mL | 750 mg/3 mL single-use vial | Benzyl benzoate 1500 mg and refined castor oil 885 mg per vial |
| Nebido (UK)2 | Grunenthal Ltd | 250 mg per mL | 1000 mg/4 mL ampoule or vial | Benzyl benzoate 2000 mg per 4 mL (500 mg/mL); castor oil, refined |
Sources in this part
Human studies
Of the studies below, T4DM enrolled men described as without pathological hypogonadism, outside the Aveed label population of adult men with primary or hypogonadotropic hypogonadism.1
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Schubert and colleagues, 2004; Minnemann and colleagues, 20088,9 | Open-label, randomized, prospective; enanthate comparator for 30 weeks, then follow-up on TU | 40 hypogonadal men (testosterone under 5 nmol/L), 20 per group | TU 1000 mg every 6 weeks for 3 injections, then after 9 weeks, against enanthate 250 mg every 3 weeks | Mean trough testosterone on TU 14.1 ± 4.5 nmol/L after the first two doses and 16.3 ± 5.7 nmol/L after the 9-week interval (± as printed, SD or SEM not stated), against under 10 nmol/L on enanthate; hemoglobin and hematocrit rose in both groups without exceeding the upper limit of normal; grip strength did not improve significantly over the first 30 weeks in either group, plasma HDL fell and PSA rose slightly. |
| Wang and colleagues, 201010 | Unblinded multicenter phase 3 trial, 31 centers | 130 men over 18 with testosterone under 300 ng/dL | 750 mg at weeks 0 and 4 and every 10 weeks, 9 injections over 84 weeks | After the first injection, average trough testosterone stayed in the adult male range (300 to 1000 ng/dL) before each injection; the authors write that injections were generally well tolerated. |
| Zitzmann and colleagues, 2013 (IPASS)11,12 | Observational, one-arm, prospective; the registry names Bayer as lead sponsor | 1,438 hypogonadal men analyzed of 1,493 enrolled, 23 countries | Up to five injections over 9 to 12 months, 6,333 in all | Low or very low libido fell from 64% to 10% after four injection intervals, by physician interview on five-point scales and with no comparator group; adverse events in 12% and adverse drug reactions in 6%, mostly mild to moderate; no case of prostate cancer. |
| Wittert and colleagues, 2021 (T4DM)14 | Randomised, double-blind, placebo-controlled phase 3b | 1007 men aged 50 to 74 with a waist of 95 cm or more and serum testosterone of 14.0 nmol/L or lower but without pathological hypogonadism, with impaired glucose tolerance or new type 2 diabetes | 1000 mg or placebo at baseline, 6 weeks, then every 3 months for 2 years | Type 2 diabetes at 2 years in 12% (55 of 443) against 21% (87 of 413) on placebo among those with data (504 and 503 randomised), relative risk 0.59 (95% CI 0.43 to 0.80); two deaths in each group. |
| Saad and colleagues, 202015 | Observational registry with untreated controls; allocation by the patient's decision | 823 hypogonadal men, 428 treated and 395 untreated | Injectable TU, up to 11 years | Unadjusted deaths 23 (5.4%) in treated men against 77 (19.5%) in untreated men, with prior cardiovascular disease at baseline lower in treated men in all three weight groups (9.9% against 23.0% in overweight men); the authors write that treatment “may contribute to reductions in mortality” and that “potential bias may exist”; Bayer supported the study and the first author is a full-time Bayer employee. |
Sources in this part
- 1Endo et al., 2025
- 2Grunenthal Ltd, 2025
- 7Shankara Narayana N, 2021
- 8Schubert et al., 2004
- 9Minnemann et al., 2008
- 10Wang et al., 2010
- 11Zitzmann et al., 2013
- 12Bayer
- 13Middleton et al., 2015
- 14Wittert et al., 2021
- 15Saad et al., 2020
- 16Endo
- 17US Food and Drug Administration, 2014
- 18Handelsman et al., 2022
- 19Pastuszak et al., 2020
For the studies of Schubert, Minnemann, Wang, Zitzmann, Middleton, Zhang, Behre and Nieschlag the sources read are PubMed records, which state no funder and no limitations passage, so those authors' own limitations are not reported here. Wang's trial has the same size, dose and length as the efficacy study that the Aveed label, from Endo, describes (130 hypogonadal men, 750 mg, 84 weeks), and the FDA review records 130 patients at 31 U.S. sites in Part C of IP157-001; the sources do not say whether these are the same study.10,1,17 Shankara Narayana and colleagues report that the testosterone product manufacturer provided no funding or other input.7
Deeper analysis: the US pivotal study of Aveed (IP157-001)
ClinicalTrials.gov lists Endo as lead sponsor of study IP157-001, a randomized, open-label pharmacokinetic and long-term safety study of 750 mg and 1000 mg in hypogonadal men, with 531 enrolled and 524 treated.16 The Aveed label describes its efficacy study as an 84-week, single-arm, open-label study of 130 hypogonadal men given 750 mg at baseline, at 4 weeks and every 10 weeks.1 Of 117 men who completed through week 24, 94% had an average testosterone within 300 to 1000 ng/dL after the third injection, 5.1% below and 0.9% above.1 In the label's 153 men (the FDA review counts 153 subjects in Parts C and C2, against 130 enrolled in Part C), acne occurred in 5.2%, injection site pain in 4.6%, a PSA above 4 ng/mL in 4.6%, and hypogonadism and estradiol increased in 2.6% each, and 7 men (4.6%) stopped because of adverse reactions, listed as hematocrit increased, estradiol increased, PSA increased, prostate cancer, mood swings, prostatic dysplasia, acne and deep vein thrombosis.1 The FDA team leader's review, counting up to 9 doses irrespective of the investigator's assessment of causality, gives 16 men (10.5%) who stopped because of adverse events and 22 men (14%) with a serious adverse event, with prostate cancer reported by 3 men in each count against 2 men (1.3%) on the label; the investigator judged one prostate cancer, reported on day 196 of Part C2, as “probably related”.17
The FDA team leader's review records four deaths in study IP157-001, two in Part C and two in Part A: the investigator rated the relationship to drug “remotely possible” for a cardiac arrest in a 52-year-old man and “definitely not related” for a myocardial infarction in a 45-year-old man and a cerebrovascular accident in a 68-year-old man; the fourth death was a homicide.17 The efficacy design has no comparator group, and the FDA team leader's review states that the Complete Response action of 2 December 2009 was “based upon a remaining Clinical deficiency”, citing “continuing safety concerns regarding reports of serious, immediate, life-threatening post-injection reactions”.17
Deeper analysis: the T4DM randomised trial
Wittert and colleagues reported T4DM in The Lancet Diabetes & Endocrinology in 2021: 1007 men in a lifestyle programme received testosterone undecanoate 1000 mg or placebo at baseline, 6 weeks and then every 3 months for 2 years.14 The first of two primary outcomes was type 2 diabetes in 55 (12%) of 443 participants with available data in the testosterone group and 87 (21%) of 413 on placebo (relative risk 0.59, 95% CI 0.43 to 0.80; p=0.0007), and the second, the mean change in 2-hour glucose, was -1.70 mmol/L on testosterone and -0.95 mmol/L on placebo.14 A haematocrit above 54% occurred in 106 (22%) of 491 on testosterone and 6 (1%) of 484 on placebo, a PSA rise trigger of 0.75 μg/mL or more in 109 (23%) of 480 on testosterone and 87 (19%) of 468 on placebo, and prespecified serious adverse events in 55 (10.9%) of 504 and 37 (7.4%) of 503.14 The authors write that “Increases in haematocrit might be treatment limiting” and that “Longer-term durability, safety, and cardiovascular effects of the intervention remain to be further investigated”.14 The trial was funded by the Australian National Health and Medical Research Council, Bayer, Eli Lilly, the University of Adelaide and WW (formerly Weight Watchers).14 In a follow-up of 303 men with glucose intolerance but without pathologic hypogonadism (outside the Aveed label population) from a 2-year placebo-controlled trial of testosterone undecanoate, Handelsman and colleagues report for the nested cohort of TU-treated men that serum testosterone and SHBG stayed 11% and 13% lower than in placebo-treated men, which they attribute to lasting effects of exogenous testosterone rather than androgen deficiency, and write that after stopping 2 years of 1000 mg injections “full reproductive hormone recovery is slow and progressive over 15 months since the last testosterone injection but may take longer than 12 months to be complete”.18
Deeper analysis: pulmonary oil microembolism in five sources
The Aveed label reports 9 POME events in 8 patients and 2 of anaphylaxis among 3,556 patients in 18 clinical trials, and the FDA team leader's review gives 4.6 POME cases per 10,000 injections in 19 trials, plus 137 cases of severe POME or anaphylaxis in about 8 years of postmarketing use outside the US, none leading to death or permanent disability up to the review.1,17 The Aveed label states that the majority of these events lasted a few minutes and resolved with supportive measures, but “some lasted up to several hours and some required emergency care and/or hospitalization”.1 The Nebido label states that suspected oily pulmonary microembolism was reported rarely in clinical trials and in postmarketing experience, defines rarely as at least 1 in 10,000 and under 1 in 1,000 injections, and says the reactions are reversible.2 Middleton and colleagues (European Journal of Endocrinology, 2015) observed POME after 56 of 3,022 injections in 43 of 347 patients at one clinic, 19 per 1000 injections (95% CI 14 to 24), 66% mild, 19% severe and 40% beginning before the injection was completed, with recurrences more frequent than by chance.13,19 The authors write that injections by experienced nurses produce “a low incidence of POME”, with no post-injection haematoma.13 Pastuszak, Hu and Freid (Sexual Medicine, 2020) report that 28 of 633 spontaneous reports to Endo were adjudicated as POME among 90,092 doses distributed, a reporting rate below 0.1% per injection annually, and the authors say one fatality 18 months after a POME event appeared unrelated to the injections.19 Of 22 cases with an outcome, 21 were resolved and 1 was not recovering; 6 of the 28 had no outcome reported and 2 had no event date.19 Four reports involved an emergency department visit, and the authors write that incorrect injection technique or incorrect product usage was a common element in 3 of the 4.19 Two of the three authors are Endo employees, Pastuszak consults for Bayer and Endo, the study was funded by Endo, and the authors name underreporting as a limitation.19
Doses reported in studies and on labels
| Source | Who | Dose reported | Route |
|---|---|---|---|
| Aveed label1 | Adult males with primary or hypogonadotropic hypogonadism | 3 mL (750 mg) at initiation, at 4 weeks, then every 10 weeks | Intramuscular, deep gluteal |
| Nebido label (UK)2 | Male hypogonadism confirmed by clinical features and biochemical tests | 1000 mg every 10 to 14 weeks; the first interval may be reduced to a minimum of 6 weeks | Intramuscular, deep gluteal |
Sources in this part
Side effects reported
What the labels list
The Aveed boxed warning states: “Serious POME reactions, involving urge to cough, dyspnea, throat tightening, chest pain, dizziness, and syncope; and episodes of anaphylaxis, including life-threatening reactions, have been reported to occur during or immediately after the administration of testosterone undecanoate injection”.1 The label adds that these reactions can occur after any injection, including the first, and that patients are observed in the healthcare setting for 30 minutes after each injection.1 The Nebido label states that its most frequently reported undesirable effects are acne and injection site pain.2
Under warnings and precautions the Aveed label also lists polycythemia, venous thromboembolism, worsening of benign prostatic hyperplasia and a potential risk of prostate cancer, blood pressure increases, effects on spermatogenesis, edema, sleep apnea and lipid changes.1 In the label's 4-month ambulatory blood pressure study of 222 patients, mean 24-hour systolic and diastolic pressure rose by 3.1 and 2.0 mm Hg in the 139 men with acceptable recordings.1
Findings in studies
In IPASS the most common adverse drug reactions were an increase in hematocrit, an increase in PSA and injection site pain, each under 1%.11 In Middleton and colleagues the mean haematocrit was 0.44 ± 0.04, with 25 men (7%) above 0.50, 14 (4%) above 0.52 and 3 (1%) above 0.54, which the authors describe as a minor problem rarely requiring treatment other than optimising the inter-injection interval.13 In T4DM, in men without pathologic hypogonadism, a haematocrit above 54% occurred in 106 of 491 on testosterone and 6 of 484 on placebo, a different threshold and population from the figures above.14
Bloodwork and markers
Sources in this part
The Milligram app lists total testosterone, free testosterone, estradiol, hematocrit, lipids and PSA as its markers for testosterone undecanoate injection. The Aveed label states that hematocrit is checked before starting treatment, that “If hematocrit becomes elevated, stop therapy until hematocrit decreases to an acceptable level”, that PSA, hemoglobin, hematocrit and lipid concentrations are monitored periodically, and that blood pressure is measured periodically.1
Regulatory and anti-doping status
The FDA approved Aveed on 5 March 2014, the US approval date given by Pastuszak and colleagues, after Complete Response actions on 2 December 2009 and 29 May 2013, and an advisory committee meeting in April 2013 that was split on safety, 9 yes and 9 no, but 17 to 1 that the proposed risk mitigation strategy and product labeling needed improvement.19,17
The Aveed label states that Aveed contains testosterone, “a Schedule III controlled substance in the Controlled Substances Act”, and 21 CFR 1308.13 lists testosterone among Schedule III anabolic steroids, “including its salts, esters and ethers”.1,20 The World Anti-Doping Agency's 2026 Prohibited List places anabolic agents in S1, prohibited at all times in and out of competition, and anabolic androgenic steroids in S1.1 “When administered exogenously, including but not limited to”, followed by a list that includes testosterone.21
Storage and handling
Sources in this part
The Aveed label states storage at controlled room temperature 25ºC, with excursions permitted to 15ºC to 30ºC, in the original carton until the date indicated.1 The Nebido label states that it does not require any special storage conditions, and that at cold storage temperatures the oil-based solution might temporarily change, for example in viscosity and cloudiness.2
What is not known
The Aveed label gives no half-life for testosterone undecanoate, and none of the cited sources gives a bioavailability figure, so the app's 95% rests on none of them.1
The FDA review's half-life of 53.46 days is from a phase 1 study of 14 men whose own report is not among the sources cited, in which serum testosterone was measured up to 8 weeks (56 days) after the dose, and the sources read do not say whether it is the same study as the 14-man castor oil study of Behre and colleagues, which gave 33.9 days.3,5
A 2016 paper by Gan, Bouloux and Quinton on the prolonged washout of exogenous testosterone after testosterone undecanoate depot injection in men with congenital hypogonadotrophic hypogonadism has no summary text in its PubMed record, so its results are not reported here.22
The cardiovascular outcomes study on the Aveed label, TRAVERSE, tested a topical gel in men with a history of cardiovascular disease or multiple risk factors (major adverse cardiovascular events 7.0% on gel, 7.3% on placebo); none of the cited sources is a cardiovascular outcomes trial of testosterone undecanoate injection, and the T4DM authors write that its cardiovascular effects remain to be further investigated.1,14
Labels from countries other than the US and the UK were not among the cited sources.
Frequently asked questions
What is the half-life of testosterone undecanoate injection?
The app uses a half-life of 53 days (1272 hours), and the FDA clinical pharmacology review of Aveed reports a mean half-life of 53.46 days in a phase 1 study of 14 hypogonadal men given 1000 mg.3 Other sources give 33.9 ± 4.9 days (Behre and colleagues, castor oil), 18.3 ± 2.3 and 23.7 ± 2.7 days (Zhang and colleagues) and 90 ± 40 days (the Nebido label, for the release rate), and the Aveed label states no half-life for the ester.5,4,2,1
How long does testosterone undecanoate injection take to peak?
What is pulmonary oil microembolism with testosterone undecanoate injection?
The Aveed label describes serious POME reactions as involving urge to cough, dyspnea, throat tightening, chest pain, dizziness and syncope, during or immediately after the injection.1 The label adds that some lasted up to several hours and some required emergency care and/or hospitalization.1 The FDA team leader's review states that the exact mechanism for these reactions (POME and anaphylaxis) has not been elucidated, and that POME is believed to follow from the castor oil in Aveed.17
How common is pulmonary oil microembolism with testosterone undecanoate injection?
The sources give different figures: 9 POME events in 8 patients among 3,556 patients in 18 trials on the Aveed label, “rarely” (at least 1 in 10,000 and under 1 in 1,000 injections) on the Nebido label, 19 per 1000 injections in the clinic of Middleton and colleagues, and 28 adjudicated reports among 90,092 distributed doses in Pastuszak and colleagues.1,2,13,19 They count different things: patients, injections and distributed doses.
Is testosterone undecanoate injection banned by WADA?
The WADA 2026 Prohibited List places anabolic androgenic steroids in S1.1, prohibited at all times in and out of competition, with the wording “When administered exogenously, including but not limited to” followed by a list that includes testosterone and ends “and other substances with a similar chemical structure or similar biological effect(s) including their esters”.21
What is the bioavailability of testosterone undecanoate injection?
The app lists 95%, and none of the cited sources gives a bioavailability percentage for the injection. The Nebido label states that the depot preparation circumvents the first-pass effect.2
Guides, tools and comparisons
References
- Endo USA, Inc. Aveed (testosterone undecanoate) injection, for intramuscular use, CIII. DailyMed label, revised July 2025. DailyMed label
- Grunenthal Ltd. Nebido 1000 mg/4 ml solution for injection. Summary of Product Characteristics, electronic medicines compendium (UK), revised 15 December 2025. UK SmPC
- US Food and Drug Administration, Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s), NDA 022219 (Aveed, testosterone undecanoate; sponsor Endo Pharmaceuticals). 2014. FDA review
- Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. J Androl 1998. PMID 9876028
- Behre HM, Abshagen K, Oettel M, Hubler D, Nieschlag E. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol 1999. PMID 10229906
- Nieschlag E, Buchter D, Von Eckardstein S, Abshagen K, Simoni M, Behre HM. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. Clin Endocrinol 1999. PMID 10619981
- Shankara Narayana N, Ly LP, Jayadev V, Fennell C, Savkovic S, Conway AJ, Handelsman DJ. Optimal injection interval for testosterone undecanoate treatment of hypogonadal and transgender men. Endocr Connect 2021. PMC8346198
- Schubert M, Minnemann T, Hubler D, et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004. PMID 15531493
- Minnemann T, Schubert M, Freude S, et al. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism. J Endocrinol Invest 2008. PMID 18852533
- Wang C, Harnett M, Dobs AS, Swerdloff RS. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial. J Androl 2010. PMID 20133964
- Zitzmann M, Mattern A, Hanisch J, Gooren L, Jones H, Maggi M. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med 2013. PMID 22812645
- Bayer. Use of Nebido to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice (IPASS Nebido). ClinicalTrials.gov NCT00410306. NCT00410306
- Middleton T, Turner L, Fennell C, et al. Complications of injectable testosterone undecanoate in routine clinical practice. Eur J Endocrinol 2015. PMID 25637074
- Wittert G, Bracken K, Robledo KP, et al. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol 2021. PMID 33338415
- Saad F, Doros G, Haider KS, Haider A. Differential effects of 11 years of long-term injectable testosterone undecanoate therapy on anthropometric and metabolic parameters in hypogonadal men with normal weight, overweight and obesity in comparison with untreated controls: real-world data from a controlled registry study. Int J Obes 2020. PMC7260126
- Endo USA Inc. Long-term Safety Study of Intramuscular Injections of 750 mg and 1000 mg Testosterone Undecanoate in Hypogonadal Men (study IP157-001). ClinicalTrials.gov NCT00467870. NCT00467870
- US Food and Drug Administration, Center for Drug Evaluation and Research. Cross discipline team leader review, NDA 022219 (Aveed, testosterone undecanoate). 2014. FDA review
- Handelsman DJ, Desai R, Conway AJ, et al. Recovery of male reproductive endocrine function after ceasing prolonged testosterone undecanoate injections. Eur J Endocrinol 2022. PMID 35000898
- Pastuszak AW, Hu Y, Freid JD. Occurrence of pulmonary oil microembolism after testosterone undecanoate injection: a postmarketing safety analysis. Sex Med 2020. PMC7261689
- US Government Publishing Office. 21 CFR 1308.13 Schedule III. Electronic Code of Federal Regulations. 21 CFR 1308.13
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA 2026 list
- Gan EH, Bouloux PM, Quinton R. Unexpectedly prolonged washout period of exogenous testosterone after discontinuation of intramuscular testosterone undecanoate depot injection (Nebido or Reandron) in men with congenital hypogonadotrophic hypogonadism. Clin Endocrinol 2016. PMID 26732131